Anand Rathi's research report on Aarti Industries
Aarti had entered into a 20-year agreement to secure nitric acid from Deepak Fertilisers valued at ~Rs80bn w.e.f. 1 st Apr’23 and specifications based on formula-linked pricing. This secures its RM and enables it to focus on growth opportunities, and introduce value-added products and value chains for niche applications. We are positive on Aarti’s long-term performance and expect its revenue/EBITDA/PAT to clock 14%/24%/ 28% CAGRs over FY23-25 on utilisation picking up at the recently commissioned capacities, the start of revenue from long-term contracts and the rising share of downstream and value-added products. The key short-term moniterables are demand slowdown in discretionary end-user industries, the challenging business environment (higher RM and utility costs) and volatile margins.
Outlook
We maintain our Buy rating at a revised TP of Rs800, valuing the company at 33x FY25e (adjusting for the hiving off of the pharma business).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.